Yale’s Kevan Herold was the senior investigator on a clinical trial which showed that the drug teplizumab — recently approved for pediatric patients with Stage 3 Type 1 diabetes — delays the progression of the disease.
[email protected] (Yale News)
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0